Empowered Funds LLC Purchases 6,113 Shares of Medpace Holdings, Inc. $MEDP

by · The Markets Daily

Empowered Funds LLC increased its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) by 31.2% during the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 25,730 shares of the company’s stock after acquiring an additional 6,113 shares during the quarter. Empowered Funds LLC’s holdings in Medpace were worth $12,355,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. AQR Capital Management LLC grew its stake in Medpace by 65.1% in the third quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company’s stock valued at $518,170,000 after acquiring an additional 404,226 shares during the period. Arrowstreet Capital Limited Partnership raised its position in shares of Medpace by 205.8% during the third quarter. Arrowstreet Capital Limited Partnership now owns 314,150 shares of the company’s stock worth $161,523,000 after purchasing an additional 211,411 shares during the period. Franklin Resources Inc. lifted its holdings in shares of Medpace by 158.6% during the 4th quarter. Franklin Resources Inc. now owns 299,472 shares of the company’s stock valued at $168,198,000 after purchasing an additional 183,645 shares in the last quarter. Norges Bank bought a new position in shares of Medpace during the 4th quarter valued at about $102,156,000. Finally, Goldman Sachs Group Inc. lifted its holdings in shares of Medpace by 92.4% during the 4th quarter. Goldman Sachs Group Inc. now owns 347,049 shares of the company’s stock valued at $194,920,000 after purchasing an additional 166,654 shares in the last quarter. 77.98% of the stock is currently owned by institutional investors.

Medpace Price Performance

Shares of Medpace stock opened at $585.49 on Thursday. The firm has a market cap of $16.34 billion, a price-to-earnings ratio of 34.32, a price-to-earnings-growth ratio of 2.55 and a beta of 1.15. The stock’s 50-day moving average is $501.76 and its 200-day moving average is $493.30. Medpace Holdings, Inc. has a one year low of $373.00 and a one year high of $677.90.

Medpace (NASDAQ:MEDP – Get Free Report) last posted its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The business had revenue of $707.33 million during the quarter, compared to the consensus estimate of $689.51 million. During the same period last year, the company earned $3.10 earnings per share. Medpace’s quarterly revenue was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, equities analysts expect that Medpace Holdings, Inc. will post 17.54 EPS for the current year.

Insiders Place Their Bets

In other news, General Counsel Stephen P. Ewald sold 16,349 shares of the firm’s stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the completion of the transaction, the general counsel directly owned 20,343 shares of the company’s stock, valued at $9,154,350. This trade represents a 44.56% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Susan E. Burwig sold 7,500 shares of the firm’s stock in a transaction that occurred on Tuesday, July 28th. The stock was sold at an average price of $600.00, for a total transaction of $4,500,000.00. Following the transaction, the vice president directly owned 62,984 shares of the company’s stock, valued at $37,790,400. This represents a 10.64% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 31,087 shares of company stock valued at $16,203,054 in the last quarter. 20.50% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on MEDP. Robert W. Baird increased their target price on Medpace from $547.00 to $624.00 and gave the stock a “neutral” rating in a research note on Friday, July 24th. TD Cowen lifted their price target on shares of Medpace from $419.00 to $492.00 and gave the company a “hold” rating in a research note on Friday, July 24th. Royal Bank Of Canada upped their price target on shares of Medpace from $484.00 to $692.00 and gave the company an “outperform” rating in a report on Friday, July 24th. Barclays set a $600.00 price objective on shares of Medpace in a research report on Thursday, July 23rd. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of Medpace in a report on Thursday, July 2nd. Two equities research analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $584.18.

Read Our Latest Stock Report on MEDP

Medpace Profile

(Free Report)

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.

Featured Stories

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report).